StreetInsider.com News Articles

BeOne Medicines (ONC) PT Raised to $425 at Morgan Stanley

Fri, 16 Oct 2026 08:42:14 -0400

Morgan Stanley raised its price target on BeOne Medicines (NASDAQ: ONC) to $425.00 (from $405.00) while maintaining a Overweight rating.

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

Investing.com -- Jefferies analysts identified their preferred mid-cap biotechnology stocks ahead of third-quarter earnings, with Oncorus (ONC) emerging as their top commercial pick, followed by Revolution Medicines (RVMD) and Alnylam Pharmaceuticals (ALNY). The firm made several price target adjustments across its coverage universe while maintaining buy ratings on select names.

The analysts noted they are closely monitoring earnings results for specific catalysts, including first revenue reports, potential earnings beats, and pipeline updates across their mid-cap biotech coverage.

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Form 4 BeOne Medicines Ltd. For: Oct 13 Filed by: Wang Xiaodong

Thu, 15 Oct 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20261015/27194125.html

BeOne Medicines (ONC) PT Raised to $459 at RBC Capital

Thu, 08 Oct 2026 08:27:07 -0400

RBC Capital analyst Leonid Timashev raised the price target on BeOne Medicines (NASDAQ: ONC) to $459.00 (from $450.00) while maintaining a Outperform rating.

BeOne Medicines (ONC) PT Raised to $420 at Truist Securities

Wed, 07 Oct 2026 07:13:17 -0400

Truist Securities analyst Greg Renza raised the price target on BeOne Medicines (NASDAQ: ONC) to $420.00 (from $418.00) while maintaining a Buy rating.

Form 4 BeOne Medicines Ltd. For: Sep 30 Filed by: Lee Chan Henry

Fri, 02 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261002/27143198.html

BeOne Medicines (ONC) PT Raised to $445 at JPMorgan

Thu, 01 Oct 2026 09:06:56 -0400

JPMorgan analyst Jessica Fye raised the price target on BeOne Medicines (NASDAQ: ONC) to $445.00 (from $425.00) while maintaining a Overweight rating.

Form 4 BeOne Medicines Ltd. For: Sep 28 Filed by: Wang Xiaodong

Wed, 30 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260930/27129443.html

Form 4 BeOne Medicines Ltd. For: Sep 14 Filed by: BAKER JULIAN

Fri, 18 Sep 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260918/27081485.html

BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens on Serial Innovation

Tue, 15 Sep 2026 05:31:17 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $405.00 price target on BeOne Medicines (NASDAQ: ONC).

The analyst commented, "BeOne Medicines, Ltd. is a global oncology company with a strong commercial and R&D footprint. Its flagship product, BRUKINSA (zanubrutinib), has become the leading BTK inhibitor in the U.S., approved across five indications. The company is expanding its hematology franchise, as evidenced by its recent approval of sonrotoclax in China, and rapidly building a differentiated solid tumor pipeline. BeOne's strategy emphasizes serial innovation, deep pipeline synergy, and global market penetration. Recent events: 3Q26 U.S. approval for TEVIMBRA-based regimen for first-line

Form 4 BeOne Medicines Ltd. For: Sep 08 Filed by: Wang Xiaodong

Thu, 10 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260910/27049175.html

BeOne Medicines (ONC) PT Raised to $415 at Barclays

Thu, 10 Sep 2026 05:06:28 -0400

Barclays analyst Peter Lawson raised the price target on BeOne Medicines (NASDAQ: ONC) to $415.00 (from $407.00) while maintaining a Overweight rating.

Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin

Thu, 27 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26991170.html

Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin

Thu, 27 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26991170.html

Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin

Thu, 27 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26991170.html

FDA approves BeOne's Tevimbra combo for HER2+ stomach cancer